{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe term \"high affinity\" antibody as used herein refers to an antibody having 1X 10 to the target antigen <sup>-7</sup> M or less, more preferably 5X 10 <sup>-8</sup> M or less, even more preferably 1X 10 <sup>-8</sup> M or less, even more preferably 5X 10 <sup>-9</sup> M or less, and even more preferably 1X 10 <sup>-9</sup> M or lower KD value.\nThe term \"IC50\", also referred to as \"half inhibitory concentration\", as used herein, refers to the concentration of inhibitor (e.g., VEGF antibody) required for 50% inhibition of a target, e.g., an enzyme, cell, receptor, cytokine, etc."}
{"final_json": [{"molecule_name": "antibody", "protein_target_name": "target antigen", "binding_metric": "KD", "value": "<1X 10^-9", "unit": "M"}, {"molecule_name": "VEGF antibody", "protein_target_name": "enzyme, cell, receptor, cytokine, etc.", "binding_metric": "IC50", "value": null, "unit": null}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe IC50 values in Table 4 also show that the neutralizing activity of the P30-10-26 and P30-10-16 molecules is superior to that of Bevacizumab.\nThe IC50 values of the two modified molecules, namely P30-10-26 and P30-10-16, are improved by about 1 time compared with the IC50 value of a control antibody Bevacizumab, and the P30-10-9 molecule is slightly superior to the Bevacizumab."}
{"final_json": [{"molecule_name": "P30-10-26", "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": null}, {"molecule_name": "P30-10-16", "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": null}, {"molecule_name": "P30-10-9", "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": null}, {"molecule_name": "Bevacizumab", "protein_target_name": null, "binding_metric": "IC50", "value": null, "unit": null}]}
